NRG A Phase II Evaluation of Copanlisib (BAY 80-6946); (IND #130822); A Selective Inhibitor of PI3KCA; in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Adult CIRB - Late Phase Emphasis Completed Completed